On September 27, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval to selpercatinib (Retevmo^®) for adult and pediatric patients aged 2 years and older with advanced or metastatic medullary thyroid cancer (MTC) with an RET variant, as detected by an FDA-approved test, who require systemic therapy.

On September 17, 2024, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda^®) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM).